Here are some medtech stories we missed this week but thought were still worth mentioning.
1. AMNIOX touts new umbilical cord study
AMNIOX Medical announced that it has published the results of 3 studies that demonstrate the effectiveness of umbilical cord tissue for treating chronic wounds, according to an April 7 press release. The company’s cryopreserved human umbilical cord tissue, NEOX Cord 1K was tested on 29 patients who needed a wound allograft to treat chronic diabetic foot ulcers. Twenty-eight of the 32 wounds showed complete healing with a success rate of 87.5%. In another test, 57 patients with chronic, lower-extremity ulcers received the treatment. Fifty-one out of 64 wounds with a healing rate of 79.7% had complete healing. The third study tested 31 patients who had lower extremity ulcers with exposed bone, tendon, muscle or joint capsule with underlying osteomyelitis. Twenty-six out of 33 wounds had completely healed, resulting in a healing rate of 78%.
2. InVivo Therapeutics enrolls another patient in study
InVivo Therapeutics announced in an April 5 press release that it has enrolled a new patient into its Inspire study that is meant to test the benefits of the Neuro-Spinal Scaffold. The surgery was performed on the patient 42 hours after injury at the Carolinas Medical Center in Charlotte, N.C. The addition of this patient makes the total of enrolled patients 14. The Neuro-Spinal Scaffold is designed to support appositional healing and reduce post-traumatic cavity formation while sparing white matter and allowing for neural regeneration across the healed wound epicenter.
3. Occlutech receives CE Mark
Occlutech has received European CE Mark for its Perimembranous Ventricular Septal Defect (PmVSD) Occluder, according to an April 5 press release. The PmVSD is an implant that is designed for the minimally invasive closure of perimembranous ventricular septal defects. It is made with a flexible nitinol wire mesh with shape memory properties.